BR112021017801A2 - Anticorpos biespecíficos anti-vbeta17/anti-cd123 - Google Patents

Anticorpos biespecíficos anti-vbeta17/anti-cd123

Info

Publication number
BR112021017801A2
BR112021017801A2 BR112021017801A BR112021017801A BR112021017801A2 BR 112021017801 A2 BR112021017801 A2 BR 112021017801A2 BR 112021017801 A BR112021017801 A BR 112021017801A BR 112021017801 A BR112021017801 A BR 112021017801A BR 112021017801 A2 BR112021017801 A2 BR 112021017801A2
Authority
BR
Brazil
Prior art keywords
antibodies
vbeta17
bispecific
bispecific anti
methods
Prior art date
Application number
BR112021017801A
Other languages
English (en)
Inventor
S Grewal Iqbal
Alejandro Sepulveda Manuel
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112021017801A2 publication Critical patent/BR112021017801A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos biespecíficos anti-vbeta17/anti-cd123. a presente invenção refere-se a anticorpos biespecíficos anti-vbeta17/cd123 ou fragmentos de ligação a antígeno dos mesmos. também descritos são ácidos nucleicos que codificam os anticorpos, composições compreendendo os anticorpos, métodos de produção dos anticorpos e métodos de uso dos anticorpos.
BR112021017801A 2019-03-11 2020-03-11 Anticorpos biespecíficos anti-vbeta17/anti-cd123 BR112021017801A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11
PCT/IB2020/000342 WO2020183245A2 (en) 2019-03-11 2020-03-11 ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Publications (1)

Publication Number Publication Date
BR112021017801A2 true BR112021017801A2 (pt) 2022-01-18

Family

ID=71670296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017801A BR112021017801A2 (pt) 2019-03-11 2020-03-11 Anticorpos biespecíficos anti-vbeta17/anti-cd123

Country Status (12)

Country Link
US (1) US20220127359A1 (pt)
EP (1) EP3937977A2 (pt)
JP (1) JP7566766B2 (pt)
KR (1) KR20210138033A (pt)
CN (1) CN113874400A (pt)
AU (1) AU2020235475A1 (pt)
BR (1) BR112021017801A2 (pt)
CA (1) CA3132916A1 (pt)
IL (1) IL286147A (pt)
MA (1) MA55305A (pt)
MX (1) MX2021010857A (pt)
WO (1) WO2020183245A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
MX2023001708A (es) * 2020-08-10 2023-05-04 Janssen Biotech Inc Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería.
KR20230084507A (ko) * 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
CA3237038A1 (en) * 2021-11-01 2023-05-04 Janssen Biotech, Inc. Compositions and methods for the modulation of beta chain-mediated immunity
AU2023217968A1 (en) * 2022-02-09 2024-09-26 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
WO2024166047A1 (en) * 2023-02-09 2024-08-15 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6084087A (en) * 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ES2340857T3 (es) 1997-09-16 2010-06-10 Centocor Ortho Biotech Inc. Metodo para la sintesis quimica completa y emsamblaje de genes y genomas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
CN104168916B (zh) * 2012-03-02 2017-07-04 中央研究院 抗上皮细胞黏着分子(EpCAM)抗体及其使用方法
HUE048791T2 (hu) * 2014-09-05 2020-09-28 Janssen Pharmaceutica Nv CD123 kötõszerek és alkalmazásaik
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CA3065929A1 (en) * 2017-06-01 2018-12-06 Michael Wayne SAVILLE Bispecific antibodies that bind cd123 and cd3

Also Published As

Publication number Publication date
KR20210138033A (ko) 2021-11-18
JP2022523442A (ja) 2022-04-22
IL286147A (en) 2021-10-31
MA55305A (fr) 2022-01-19
WO2020183245A2 (en) 2020-09-17
CN113874400A (zh) 2021-12-31
CA3132916A1 (en) 2020-09-17
EP3937977A2 (en) 2022-01-19
JP7566766B2 (ja) 2024-10-15
AU2020235475A1 (en) 2021-09-30
WO2020183245A3 (en) 2020-12-03
MX2021010857A (es) 2021-12-15
US20220127359A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
EA202092735A1 (ru) Антагонизирующее cd73 антитело
MX2021011696A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112015022260A2 (pt) anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
BR112021022089A2 (pt) Materiais e métodos para modulação da imunidade mediada por células t
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
WO2018194496A3 (ru) Моноклональное антитело к pd-l1
MX2020000288A (es) Cromatografia.
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
UY38672A (es) Anticuerpo monoclonal que se une específicamente a gitr
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
BR112022020410A2 (pt) Anticorpos anti-phf-tau e usos dos mesmos
BR112023019546A2 (pt) Anticorpos anti-tau e usos dos mesmos
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
BR112021026375A2 (pt) Antígenos de câncer inovadores e métodos